Monitor upcoming topline data from the chronic pain Phase 1b trial expected in Q2 2026 and progress in the IPF Phase 2 trial. The increased ATM capacity provides funding flexibility but could lead to future dilution.
Price Chart
Executive Summary
Contineum Therapeutics reported Q4 2025 financial results showing a net loss of $15.2 million and research and development expenses of $12.8 million. The company raised $93 million in a public offering and increased its at-the-market (ATM) equity offering capacity from $75 million to $100 million. They initiated patient dosing in a Phase 2 trial for IPF and expect topline data from a chronic pain trial in Q2 2026. With $262.9 million in cash, they project runway into mid-2029.
Key Financial Metrics
Key Facts
- Net loss of $15.2 million for Q4 2025, compared to $14.6 million in Q4 2024
- Cash, cash equivalents, and marketable securities totaled $262.9 million as of December 31, 2025
- Completed public offering generating $93 million in net proceeds
- Increased ATM equity offering capacity from $75 million to $100 million
- Initiated patient dosing in PROPEL-IPF Phase 2 trial for idiopathic pulmonary fibrosis
- Projected cash runway extends into mid-2029
Financial Impact
Cash increased to $262.9 million after $93 million public offering; R&D expenses decreased 2% to $12.8 million
Risk Factors
- Biotech stocks are inherently volatile with binary outcomes based on clinical trial results
- Increased ATM capacity could lead to significant share dilution if utilized
- Company remains in clinical stage with no approved products, dependent on successful trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-015159 |
| Document: ctnm-20260305.htm | 0001628280-26-015159 |
| Document: a2026_marchx8kxex-11.htm | 0001628280-26-015159 |
| Document: a2026_marchx8kxex-51.htm | 0001628280-26-015159 |
| Document: 0001628280-26-015159-index-headers.html | 0001628280-26-015159 |
| Document: 0001628280-26-015159-index.html | 0001628280-26-015159 |
| Document: 0001628280-26-015159.txt | 0001628280-26-015159 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 8, 2026 12w ago | Insider Cluster | $15.45 $13.12 | ▼ −15.08% | ▼ −16.71% | $13.12 (−15.08%) |
Jul 2, 2026 13w ago | Insider Cluster | $15.10 $12.49 | ▼ −17.28% | ▼ −20.29% | $13.12 (−13.11%) |
Jul 1, 2026 13w ago | Insider Cluster | $15.10 $12.49 | ▼ −17.28% | ▼ −20.29% | $13.12 (−13.11%) |
Mar 5, 2026 30w ago | 8-K | $13.88 $13.09 | ▼ −5.69% | ▼ −18.47% | $13.12 (−5.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access